|
Collaborative Work can Lead to Innovation
|
|
|
| By
Dr Ralph Fink
|
|
|
|
In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during development due to these challenging properties.
|
|
|
|
Open Alliance
|
|
|
|
A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.
|
|
|
|
Solid Dispersions by Hot-Melt Extrusion
|
|
|
| By
Andreas Gryczke
|
|
|
|
The advantages and disadvantages of hot-melt extrusion in solid dispersion formulations.
|
|
|
|
Rebranding Lipophilic Excipients
|
|
|
| By
Shaukat Ali
,
Nina Karpynec
|
|
|
|
Solubilizers play an important role in dissolving poorly soluble molecules. As the number of poorly soluble lipophilic and/or hydrophobic molecules increases—whether as "brick dusts" or waxy substances—the industry is struggling to identify the appropriate lipophilic excipients (surfactants, solubilizers, solvents or polymers) that can be used to develop such poorly soluble formulations into solid dosages and other forms of pharmaceutical products.
|
|
|
|
Bioavailability Enhancement
|
|
|
| By
Thomas Reintjes
,
Felicitas Guth
|
|
|
|
Soluplus®, a graft copolymer of PEG comprising polyvinyl acetate and polyvinyl caprolactam, was specially designed to solubilize poorly water-soluble drugs.
|
|
|
|
Lipid-Based Formulations
|
|
|
| By
Wei-Guo Dai
|
|
|
|
Development of viable dosage forms for poorly water-soluble compounds continues to be a significant challenge for formulation scientists, and insufficient bioavailability of such compounds may result in development delays or failures.
|
|
|
|
Spray Drying of Amorphous Dispersions
|
|
|
| By
Bend Research
|
|
|
|
Spray drying is a key process for manufacturing amorphous dispersions because of its breadth of applicability. The wide range of potential atomization techniques and controllable drying kinetics enables amorphous spray-dried dispersions (SDDs) to be produced from a wide variety of active pharmaceutical ingredients (APIs).
|
|
|
|
Addressing the Solubility Challenge
|
|
|
|
A Q&A with Karl Kolter, PhD, Head of Pharmaceutical Excipients R&D, BASF
|
|
|
